Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-3-642-74643-7_100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of mTOR activation in steroid-resistant asthma: insights from particulate matter-induced mouse model and patient studies.
Inflamm Res
January 2025
Institute of Allergy and Clinical Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.
Particulate matter (PM) exposure has been proposed as one of the causes of steroid resistance. However, studies investigating this using patient samples or animals are still lacking. Therefore, in this study, we aimed to investigate the changes in cytokines and mTOR (mammalian target of rapamycin) activation in patients with steroid resistant asthma and the role of mTOR in a mouse model of steroid resistant asthma induced by PM.
View Article and Find Full Text PDFComplex management of GS (Good's syndrome) with persistent COVID-19 infection and polymicrobial infections: A case report.
Heliyon
January 2025
Zhongshan Hospital (Xiamen), Fudan University, Xiamen City, 361015, China.
This case report highlights the diagnostic and therapeutic complexities faced by a 56-year-old female with Good's syndrome (GS), who presented with persistent Coronavirus Disease 2019 (COVID-19) infection alongside spp, , and co-infection, which collectively contributed to severe pulmonary involvement. The report further emphasizes a multifaceted treatment approach, incorporating antivirals, antifungals, antimicrobials, immunoglobulins, and antifibrotic therapy, which ultimately led to an improvement in the patient's condition. It underscored the intricate challenges of managing immunocompromised patients with multiple concurrent infections.
View Article and Find Full Text PDFStudy of Outcomes of Mucormycosis in COVID-19 Patients at a Tertiary Care Hospital in Central India: A Retrospective Study.
Cureus
December 2024
Department of Medicine, Government Medical College and Hospital, Nagpur, IND.
Background The COVID-19 pandemic has posed unprecedented challenges to the global healthcare system. Among the various complications, mucormycosis, a fungal infection caused by the Mucorales order, has emerged as a significant threat, particularly in immunocompromised individuals. This study aims to evaluate the outcomes of mucormycosis in COVID-19 patients treated at a tertiary care hospital in Central India.
View Article and Find Full Text PDFSevere dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient.
IDCases
December 2024
Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), Laboratory of Hematology, University of Liège, Liège, Belgium.
Bispecific antibody is a new treatment for hematological disease, especially for lymphoma, myeloma and acute lymphoblastic leukemia. This class of treatment presents the same kind of side effect as CAR-T cell which are immune-mediated. Nevertheless, infectious complication remains a major concerns with related mortality.
View Article and Find Full Text PDFNavigating the complexities of azole antifungal therapy through pharmacokinetic concepts: a case of prolonged isavuconazole toxicity.
J Antimicrob Chemother
January 2025
Department of Infectious Diseases, CHU de Saint-Etienne, Saint-Etienne 42055, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!